Trade BridgeBio Pharma, Inc. - BBIO CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Trading Conditions
| Spread | 0.21 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026207% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003985% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
BridgeBio Pharma Inc ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Key Stats
| Prev. Close* | 32.44 |
| Open* | 34.13 |
| 1-Year Change* | 270.58% |
| Day's Range* | 32.14 - 34.13 |
| 52 wk Range | 6.64-36.36 |
| Average Volume (10 days) | 1.19M |
| Average Volume (3 months) | 32.67M |
| Market Cap | 4.93B |
| P/E Ratio | -100.00K |
| Shares Outstanding | 173.97M |
| Revenue | 9.43M |
| EPS | -3.91 |
| Dividend (Yield %) | N/A |
| Beta | 0.99 |
| Next Earnings Date | Feb 21, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Dec 8, 2023 | 32.44 | -1.25 | -3.71% | 33.69 | 34.25 | 32.03 |
| Dec 7, 2023 | 33.53 | 1.37 | 4.26% | 32.16 | 33.64 | 32.16 |
| Dec 6, 2023 | 32.34 | 0.72 | 2.28% | 31.62 | 32.92 | 31.25 |
| Dec 5, 2023 | 31.54 | 0.13 | 0.41% | 31.41 | 32.13 | 30.70 |
| Dec 4, 2023 | 31.88 | 1.27 | 4.15% | 30.61 | 32.31 | 30.27 |
| Dec 1, 2023 | 30.89 | 2.44 | 8.58% | 28.45 | 30.91 | 27.78 |
| Nov 30, 2023 | 28.66 | 0.14 | 0.49% | 28.52 | 29.60 | 28.27 |
| Nov 29, 2023 | 28.42 | -0.39 | -1.35% | 28.81 | 29.53 | 28.32 |
| Nov 28, 2023 | 28.78 | -0.67 | -2.28% | 29.45 | 29.91 | 28.34 |
| Nov 27, 2023 | 29.72 | 0.57 | 1.96% | 29.15 | 30.10 | 28.66 |
| Nov 24, 2023 | 29.36 | 0.22 | 0.75% | 29.14 | 29.90 | 28.91 |
| Nov 22, 2023 | 29.43 | 0.98 | 3.44% | 28.45 | 29.43 | 28.13 |
| Nov 21, 2023 | 28.24 | -0.36 | -1.26% | 28.60 | 28.75 | 28.00 |
| Nov 20, 2023 | 29.18 | 0.51 | 1.78% | 28.67 | 30.00 | 28.65 |
| Nov 17, 2023 | 29.20 | 0.22 | 0.76% | 28.98 | 29.53 | 28.36 |
| Nov 16, 2023 | 28.81 | -0.64 | -2.17% | 29.45 | 29.46 | 28.38 |
| Nov 15, 2023 | 29.45 | 0.57 | 1.97% | 28.88 | 30.81 | 28.45 |
| Nov 14, 2023 | 29.43 | 0.40 | 1.38% | 29.03 | 29.73 | 28.70 |
| Nov 13, 2023 | 27.46 | 0.35 | 1.29% | 27.11 | 27.77 | 26.03 |
| Nov 10, 2023 | 27.05 | 0.02 | 0.07% | 27.03 | 27.07 | 26.33 |
BridgeBio Pharma, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Wednesday, February 21, 2024 | ||
| Time (UTC) 13:30 | Country US
| Event Q4 2023 BridgeBio Pharma Inc Earnings Release Q4 2023 BridgeBio Pharma Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 77.648 | 69.716 | 8.249 | 40.56 | 0 |
| Revenue | 77.648 | 69.716 | 8.249 | 40.56 | 0 |
| Cost of Revenue, Total | 3.434 | 3.114 | 0 | 2.5 | 0 |
| Gross Profit | 74.214 | 66.602 | 8.249 | 38.06 | 0 |
| Total Operating Expense | 589.85 | 646.348 | 482.731 | 307.216 | 164.333 |
| Selling/General/Admin. Expenses, Total | 143.189 | 192.21 | 145.684 | 94.353 | 43.587 |
| Research & Development | 399.462 | 451.024 | 337.047 | 207.947 | 140.073 |
| Unusual Expense (Income) | 43.765 | 2.416 | -19.327 | ||
| Operating Income | -512.202 | -576.632 | -474.482 | -266.656 | -164.333 |
| Interest Income (Expense), Net Non-Operating | 35.05 | -45.645 | -32.64 | -20.719 | -0.818 |
| Other, Net | -7.5 | 35.823 | 1.634 | -1.21 | -4.3 |
| Net Income Before Taxes | -484.652 | -586.454 | -505.488 | -288.585 | -169.451 |
| Net Income After Taxes | -484.652 | -586.454 | -505.488 | -288.585 | -169.451 |
| Minority Interest | 3.469 | 23.915 | 56.764 | 27.998 | 38.702 |
| Net Income Before Extra. Items | -481.183 | -562.539 | -448.724 | -260.587 | -130.749 |
| Net Income | -481.183 | -562.539 | -448.724 | -260.587 | -130.749 |
| Income Available to Common Excl. Extra. Items | -481.183 | -562.539 | -448.724 | -260.587 | -130.749 |
| Income Available to Common Incl. Extra. Items | -481.183 | -562.539 | -448.724 | -260.587 | -130.749 |
| Diluted Net Income | -481.183 | -562.539 | -448.724 | -260.587 | -130.749 |
| Diluted Weighted Average Shares | 147.473 | 144.357 | 117.995 | 105.099 | 115 |
| Diluted EPS Excluding Extraordinary Items | -3.26285 | -3.89687 | -3.80289 | -2.47944 | -1.13695 |
| Dividends per Share - Common Stock Primary Issue | 0 | ||||
| Diluted Normalized EPS | -2.96609 | -3.89687 | -3.80289 | -2.45645 | -1.30501 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 1.641 | 1.826 | 1.87 | 0.338 | 73.746 |
| Revenue | 1.641 | 1.826 | 1.87 | 0.338 | 73.746 |
| Total Operating Expense | 147.74 | 127.989 | 131.102 | 129.454 | 153.922 |
| Selling/General/Admin. Expenses, Total | 36.122 | 31.108 | 31.862 | 31.188 | 36.426 |
| Research & Development | 107.488 | 92.861 | 90.902 | 92.511 | 108.4 |
| Operating Income | -146.099 | -126.163 | -129.232 | -129.116 | -80.176 |
| Interest Income (Expense), Net Non-Operating | -14.645 | -15.004 | -15.898 | -17.408 | 88.433 |
| Other, Net | 0.041 | -1.565 | 4.56 | 6.331 | -10.816 |
| Net Income Before Taxes | -160.703 | -142.732 | -140.57 | -140.193 | -2.559 |
| Net Income After Taxes | -160.703 | -142.732 | -140.57 | -140.193 | -2.559 |
| Minority Interest | 2.804 | 2.576 | 2.979 | 2.854 | -7.297 |
| Net Income Before Extra. Items | -157.899 | -140.156 | -137.591 | -137.339 | -9.856 |
| Net Income | -157.899 | -140.156 | -137.591 | -137.339 | -9.856 |
| Income Available to Common Excl. Extra. Items | -157.899 | -140.156 | -137.591 | -137.339 | -9.856 |
| Income Available to Common Incl. Extra. Items | -157.899 | -140.156 | -137.591 | -137.339 | -9.856 |
| Diluted Net Income | -157.899 | -140.156 | -137.591 | -137.339 | -9.856 |
| Diluted Weighted Average Shares | 160.535 | 152.646 | 149.365 | 147.938 | 146.685 |
| Diluted EPS Excluding Extraordinary Items | -0.98358 | -0.91818 | -0.92117 | -0.92836 | -0.06719 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.96158 | -0.89611 | -0.86968 | -0.89445 | -0.00995 |
| Cost of Revenue, Total | 0.599 | 0.651 | 0.647 | 0.739 | 0.7 |
| Gross Profit | 1.042 | 1.175 | 1.223 | -0.401 | 73.046 |
| Unusual Expense (Income) | 3.531 | 3.369 | 7.691 | 5.016 | 8.396 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 548.853 | 888.858 | 642.824 | 568.622 | 445.223 |
| Cash and Short Term Investments | 471.922 | 836.663 | 607.093 | 545.993 | 436.086 |
| Cash & Equivalents | 376.689 | 393.772 | 356.082 | 363.773 | 436.086 |
| Prepaid Expenses | 21.922 | 32.269 | 35.592 | 22.629 | 7.087 |
| Other Current Assets, Total | 55.009 | 19.926 | 0.139 | 2.05 | |
| Total Assets | 623.036 | 1012.79 | 703.588 | 631.679 | 464.941 |
| Property/Plant/Equipment, Total - Net | 25.247 | 45.973 | 36.833 | 5.625 | 1.575 |
| Property/Plant/Equipment, Total - Gross | 1.806 | ||||
| Accumulated Depreciation, Total | -0.231 | ||||
| Long Term Investments | 31.144 | 17.05 | |||
| Other Long Term Assets, Total | 20.224 | 33.027 | 23.931 | 26.288 | 1.093 |
| Total Current Liabilities | 121.428 | 135.069 | 95.648 | 60.385 | 32.577 |
| Accounts Payable | 11.558 | 11.884 | 8.945 | 8.852 | 13.509 |
| Accrued Expenses | 101.714 | 122.89 | 79.567 | 47.455 | 15.062 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 8.156 | 0 | 5.55 | 4.078 | 4.006 |
| Total Liabilities | 1877.65 | 1883.21 | 645.682 | 223.225 | 150.062 |
| Total Long Term Debt | 1707.61 | 1705.05 | 477.43 | 91.791 | 54.507 |
| Long Term Debt | 1707.61 | 1703.81 | 475.857 | 91.791 | 54.507 |
| Minority Interest | 9.693 | 4.835 | 49.98 | 67.522 | 62.483 |
| Other Liabilities, Total | 38.917 | 38.252 | 22.624 | 3.527 | 0.495 |
| Total Equity | -1254.62 | -870.414 | 57.906 | 408.454 | 314.879 |
| Preferred Stock - Non Redeemable, Net | 478.865 | ||||
| Common Stock | 0.157 | 0.154 | 0.125 | 0.124 | 3.373 |
| Retained Earnings (Accumulated Deficit) | -1918.15 | -1436.97 | -888.755 | -440.031 | -167.359 |
| Total Liabilities & Shareholders’ Equity | 623.036 | 1012.79 | 703.588 | 631.679 | 464.941 |
| Total Common Shares Outstanding | 150.626 | 147.343 | 122.849 | 123.658 | 115 |
| Short Term Investments | 95.233 | 442.891 | 251.011 | 182.22 | |
| Redeemable Preferred Stock | 0 | ||||
| Additional Paid-In Capital | 938.703 | 841.53 | 1021.34 | 848.107 | |
| Other Equity, Total | -0.328 | -0.132 | 0.192 | 0.254 | |
| Current Port. of LT Debt/Capital Leases | 0.295 | 1.586 | |||
| Capital Lease Obligations | 1.245 | 1.573 | |||
| Treasury Stock - Common | -275 | -275 | -75 | ||
| Intangibles, Net | 28.712 | 44.934 |
| Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 587.67 | 432.884 | 552.702 | 548.853 | 642.219 |
| Cash and Short Term Investments | 543.265 | 383.794 | 491.293 | 471.922 | 591.977 |
| Cash & Equivalents | 505.213 | 302.438 | 407.368 | 376.689 | 483.235 |
| Short Term Investments | 38.052 | 81.356 | 83.925 | 95.233 | 108.742 |
| Total Receivables, Net | |||||
| Prepaid Expenses | 22.583 | 20.546 | 25.145 | 21.922 | 25.521 |
| Total Assets | 655.008 | 503.661 | 625.68 | 623.036 | 728.74 |
| Property/Plant/Equipment, Total - Net | 21.745 | 22.861 | 24.098 | 25.247 | 27.341 |
| Long Term Investments | |||||
| Other Long Term Assets, Total | 18.676 | 20.401 | 20.767 | 20.224 | 29.87 |
| Total Current Liabilities | 106.065 | 110.12 | 96.596 | 121.428 | 119.194 |
| Accounts Payable | 4.472 | 3.874 | 4.076 | 11.558 | 10.158 |
| Accrued Expenses | 95.001 | 100.036 | 85.845 | 101.714 | 101.518 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | |||||
| Other Current Liabilities, Total | 6.592 | 6.21 | 6.675 | 8.156 | 7.518 |
| Total Liabilities | 1862.55 | 1865.68 | 1851.34 | 1877.65 | 1867.16 |
| Total Long Term Debt | 1721.08 | 1718.94 | 1713.29 | 1707.61 | 1698.69 |
| Long Term Debt | 1721.08 | 1718.94 | 1713.29 | 1707.61 | 1698.69 |
| Capital Lease Obligations | |||||
| Minority Interest | 13.808 | 12.385 | 12.052 | 9.693 | 8.044 |
| Other Liabilities, Total | 21.597 | 24.242 | 29.405 | 38.917 | 41.226 |
| Total Equity | -1207.54 | -1362.02 | -1225.67 | -1254.62 | -1138.42 |
| Common Stock | 0.18 | 0.168 | 0.167 | 0.157 | 0.156 |
| Additional Paid-In Capital | 1459.6 | 1128.1 | 1106.64 | 938.703 | 917.333 |
| Retained Earnings (Accumulated Deficit) | -2392.35 | -2215.35 | -2057.46 | -1918.15 | -1780.56 |
| Treasury Stock - Common | -275 | -275 | -275 | -275 | -275 |
| Other Equity, Total | 0.034 | 0.063 | -0.012 | -0.328 | -0.348 |
| Total Liabilities & Shareholders’ Equity | 655.008 | 503.661 | 625.68 | 623.036 | 728.74 |
| Total Common Shares Outstanding | 174.132 | 161.42 | 160.435 | 150.626 | 149.367 |
| Accounts Receivable - Trade, Net | |||||
| Other Current Assets, Total | 21.822 | 28.544 | 36.264 | 55.009 | 24.721 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | |
| Intangibles, Net | 26.917 | 27.515 | 28.113 | 28.712 | 29.31 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -484.652 | -586.454 | -505.488 | -288.585 | -169.451 |
| Cash From Operating Activities | -419.494 | -497.934 | -399.714 | -253.587 | -136.643 |
| Cash From Operating Activities | 6.771 | 5.843 | 0.245 | ||
| Non-Cash Items | 24.047 | 83.736 | 90.84 | 45.913 | 10.072 |
| Cash Interest Paid | 54.443 | 29.774 | 15.322 | 6.092 | 1.574 |
| Changes in Working Capital | 34.34 | -1.059 | 14.934 | -10.915 | 22.491 |
| Cash From Investing Activities | 453.147 | -200.826 | -52.993 | -217.253 | -21.036 |
| Capital Expenditures | -6.321 | -13.246 | -7.518 | -5.138 | -18.178 |
| Other Investing Cash Flow Items, Total | 459.468 | -187.58 | -45.475 | -212.115 | -2.858 |
| Cash From Financing Activities | -13.134 | 736.446 | 447.189 | 398.792 | 501.548 |
| Financing Cash Flow Items | -0.724 | -163.695 | -41.939 | -7.272 | 14.196 |
| Issuance (Retirement) of Stock, Net | 8.076 | -179.536 | -60.872 | 368.946 | 430.974 |
| Issuance (Retirement) of Debt, Net | -20.486 | 1079.68 | 550 | 37.118 | 56.378 |
| Net Change in Cash | 20.519 | 37.686 | -5.518 | -72.048 | 343.869 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -142.732 | -484.652 | -344.082 | -203.889 | -201.33 |
| Cash From Operating Activities | -144.322 | -419.494 | -326.251 | -191.088 | -160.635 |
| Non-Cash Items | 28.579 | 24.047 | -9.872 | -20.128 | 42.625 |
| Cash Interest Paid | 22.059 | 54.443 | 47.575 | 25.435 | 18.809 |
| Changes in Working Capital | -31.802 | 34.34 | 22.592 | 29.463 | -3.814 |
| Cash From Investing Activities | 12.298 | 453.147 | 435.182 | 288.325 | 138.623 |
| Capital Expenditures | -0.012 | -6.321 | -5.52 | -4.761 | -0.859 |
| Other Investing Cash Flow Items, Total | 12.31 | 459.468 | 440.702 | 293.086 | 139.482 |
| Cash From Financing Activities | 150.249 | -13.134 | -19.511 | -20.956 | -0.16 |
| Financing Cash Flow Items | 5.231 | -0.724 | -2.192 | -1.596 | -1.23 |
| Issuance (Retirement) of Stock, Net | 145.018 | 8.076 | 3.167 | 1.126 | 1.07 |
| Issuance (Retirement) of Debt, Net | -20.486 | -20.486 | -20.486 | 0 | |
| Net Change in Cash | 18.225 | 20.519 | 89.42 | 76.281 | -22.172 |
| Cash From Operating Activities | 1.633 | 6.771 | 5.111 | 3.466 | 1.884 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| Kohlberg Kravis Roberts & Co. L.P. | Private Equity | 18.0966 | 31060971 | 0 | 2023-06-30 | MED |
| Viking Global Investors LP | Investment Advisor/Hedge Fund | 14.6359 | 25120991 | -1500000 | 2023-07-18 | MED |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 6.7973 | 11666929 | -385611 | 2023-06-30 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 4.6765 | 8026757 | 513094 | 2023-06-30 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 4.1187 | 7069360 | 1926347 | 2023-06-30 | LOW |
| Kumar (Neil) | Individual Investor | 4.1142 | 7061605 | 0 | 2023-08-17 | LOW |
| Aisling Capital Management LP | Investment Advisor/Hedge Fund | 3.5354 | 6068125 | 0 | 2023-06-30 | LOW |
| Laurion Capital Management LP | Hedge Fund | 2.767 | 4749343 | 1236584 | 2023-06-30 | HIGH |
| Cormorant Asset Management, LP | Hedge Fund | 2.429 | 4169179 | -388235 | 2023-06-30 | LOW |
| HHLR Advisors, Ltd. | Investment Advisor/Hedge Fund | 1.744 | 2993447 | -984963 | 2023-06-30 | MED |
| Pictet Asset Management Ltd. | Investment Advisor/Hedge Fund | 1.4756 | 2532716 | 1090284 | 2023-06-30 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.4096 | 2419370 | 166212 | 2023-06-30 | LOW |
| Frazier Healthcare Partners | Venture Capital | 1.1587 | 1988876 | 817226 | 2023-06-30 | LOW |
| Sequoia Capital Partners Inc. | Venture Capital | 1.0839 | 1860364 | 0 | 2023-06-30 | LOW |
| Perceptive Advisors LLC | Private Equity | 1.019 | 1748933 | -158100 | 2023-06-30 | MED |
| Fidelity Management & Research Company LLC | Investment Advisor | 0.9677 | 1660883 | -443351 | 2023-06-30 | LOW |
| D. E. Shaw & Co., L.P. | Hedge Fund | 0.9514 | 1632986 | -599035 | 2023-06-30 | MED |
| Citi Investment Research (US) | Research Firm | 0.8317 | 1427516 | -119529 | 2023-06-30 | MED |
| Homcy (Charles J) | Individual Investor | 0.7127 | 1223286 | 2459 | 2023-08-16 | LOW |
| Octagon Capital Advisors LP | Hedge Fund | 0.7103 | 1219200 | -118960 | 2023-06-30 | MED |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Trade commission
0
- 1:1
Leverage
1:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Open
Close
Short Long
BridgeBio Pharma, Inc. Company profile
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include BBP-265, a small molecule stabilizer of transthyretin, or TTR, that is in an ongoing Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor which is an ongoing Phase 2 clinical trial for the treatment of achondroplasia in pediatric patients; an AAV5 gene transfer product candidate for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD; and Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, an ongoing phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1. The company also engages in developing products for Mendelian, genetic dermatology, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; The Regents of the University of California; Leidos Biomedical Research, Inc.; the University of California, San Diego; Johns Hopkins University and University of Florida; University of Colorado Anschutz Medical Campus; Salk Institute for Biological Studies; Maze Therapeutics; UC San Francisco; the Canadian Glycomics Network (GlycoNet); the University of California; Columbia University; Mount Sinai; and Helsinn Group, as well as a clinical collaboration with Bristol Myers Squibb to evaluate the combination of BBP-398. It also has a research collaboration and option agreement with Unnatural Products Inc. to target rare diseases with potential oncology applications. The company was founded in 2015 and is headquartered in Palo Alto, California.| Industry: | Biopharmaceuticals |
3160 Porter Dr.
Suite 250
PALO ALTO
CALIFORNIA 94304
US
Income Statement
- Annual
- Quarterly
News
December RBA preview: no move expected at the final meeting of 2023
The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.
14:47, 4 December 2023
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs
12:39, 30 November 2023
Euro Zone CPI expected to continue dropping; economists warn about cutting too soon
EZ PI expected to drop further but speed of decline
08:16, 29 November 2023
A weaker Dollar drives gold higher
Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.
13:49, 28 November 2023
Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain
US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.
13:20, 28 November 2023
RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023
The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.
13:04, 28 November 2023
Crude prices slide on OPEC+ uncertainty
Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.
12:55, 28 November 2023People also watch
Still looking for a broker you can trust?
Join the 570.000+ traders worldwide that chose to trade with Capital.com